8BT logo

BriaCell Therapeutics Corp.DB:8BT Stock Report

Market Cap €28.0m
Share Price
n/a
1Y-51.5%
7D-10.2%
1D-2.6%
Portfolio Value
​
View

BriaCell Therapeutics Corp.

DB:8BT Stock Report

Market Cap: €28.0m

BriaCell Therapeutics (8BT) Stock Overview

A pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. More details

8BT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 2.8% per year over past 5 years

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

+ 1 more risk

8BT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,107 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
480,107 investors already sharing narratives
View all narratives

BriaCell Therapeutics Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BriaCell Therapeutics
Historical stock prices
Current Share PriceCA$3.00
52 Week HighCA$11.90
52 Week LowCA$2.22
Beta1.54
1 Month Change20.97%
3 Month Change-1.96%
1 Year Change-51.53%
3 Year Change-99.61%
5 Year Change-99.52%
Change since IPO-92.16%

Recent News & Updates

Recent updates

Shareholder Returns

8BTDE BiotechsDE Market
7D-10.2%-0.1%0.1%
1Y-51.5%11.4%-0.5%

Return vs Industry: 8BT underperformed the German Biotechs industry which returned 11.4% over the past year.

Return vs Market: 8BT underperformed the German Market which returned -0.5% over the past year.

Price Volatility

Is 8BT's price volatile compared to industry and market?
8BT volatility
8BT Average Weekly Movement14.1%
Biotechs Industry Average Movement7.7%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.7%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 8BT's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8BT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aBill Williamsbriacell.com

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.

BriaCell Therapeutics Corp. Fundamentals Summary

How do BriaCell Therapeutics's earnings and revenue compare to its market cap?
8BT fundamental statistics
Market cap€28.02m
Earnings (TTM)-€26.96m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.1x
P/E Ratio

Is 8BT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8BT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$30.68m
Earnings-US$30.68m

Last Reported Earnings

Apr 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-3.53
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 8BT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 02:21
End of Day Share Price 2026/07/23 00:00
Earnings2026/04/30
Annual Earnings2025/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BriaCell Therapeutics Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Ashok KumarThinkEquity LLC